Blue Dog Democrat FDA reform bill likely to focus on third-party review.
This article was originally published in The Tan Sheet
Executive Summary
FDA REFORM BILL FOCUSING ON THIRD-PARTY REVIEW PLANNED BY BLUE DOG COALITION of centrist House Democrats. A bill under development by the Blue Dog Coalition is understood to be focusing on third-party reviews as a central element and likely would avoid controversial elements such as permitting off-label information dissemination and imposing "hammers" if FDA failed to meet performance goals.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning